CytomX Therapeutics, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Sean A. McCarthy
- Full Time Employees
- 69
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 151 Oyster Point Boulevard South San Francisco CA United States of America 94080
- IPO Date
- Oct 8, 2015
- CIK
- 0001501989
- Website
- cytomx.com
- Similar Companies
- Business
- CytomX Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company specializing in the development of novel conditionally activated biologics through its proprietary Probody® therapeutic platform. The company’s pipeline includes a range of therapeutics targeting cancer, such as antibody-drug conjugates (ADCs), T-cell engagers, and immune modulators including cytokines, designed to be activated specifically within the tumor microenvironment to enhance efficacy while minimizing systemic toxicity. CytomX’s main products and services encompass the development of masked biologics that address solid tumors by leveraging its Probody technology to improve tumor targeting and immune activation. The company operates primarily in the United States from its headquarters in South San Francisco, California, and collaborates with global biopharmaceutical partners including Astellas, Moderna, Amgen, Bristol Myers Squibb, and Regeneron. Founded in 2008, CytomX has recently advanced key clinical-stage programs such as CX-2051, a masked EpCAM-targeting ADC with a novel topoisomerase-1 payload focused on advanced colorectal cancer, and CX-801, a PROBODY interferon-alpha 2b cytokine undergoing trials in metastatic melanoma and other solid tumors. Significant 2024-2025 developments include initiating Phase 1 studies for these programs and entering strategic partnerships with Astellas for T-cell engager bispecific therapeutics and Moderna for mRNA-based conditionally activated therapies in oncology. The company also established a clinical collaboration with Merck to evaluate CX-801 in combination with the anti-PD-1 therapy Keytruda (pembrolizumab). Financially, CytomX reported $143.6 million in cash, cash equivalents, and investments as of Q3 2025, supporting ongoing clinical development and extending its cash runway into 2026 following a corporate restructuring. These operational and strategic advances reflect CytomX’s focus on developing next-generation immuno-oncology therapies that improve safety and effectiveness in cancer treatment.
Bank of America Corp DE Has $47.95 Million Position in CytomX Therapeutics, Inc. $CTMX
CytomX Therapeutics: Promising Varseta-M With Comfortable Runway
CytomX Therapeutics, Inc. (CTMX) Q2 2026 Earnings Call Transcript
CytomX Therapeutics Q2 Earnings Call Highlights
CytomX Therapeutics (CTMX) Reports Q2 Loss, Lags Revenue Estimates
CytomX Therapeutics Announces Q2 2026 Financial Results and Provides Business Update
CytomX Therapeutics Appoints Alejandra Carvajal as Chief Legal Officer
CytomX Therapeutics to Report Second Quarter 2026 Financial Results on August 6, 2026
ADAR1 Capital Management LLC Sells 872,579 Shares of CytomX Therapeutics, Inc. $CTMX
CytomX Therapeutics Announces Appointment of Charles Fuchs, M.D., M.P.H., to the Board of Directors
CytomX Therapeutics (CTMX) Upgraded to Buy: Here's Why
CytomX Therapeutics, Inc. (CTMX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
CytomX Announces Expansion of Strategic Research Collaboration with Regeneron in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer
CytomX Therapeutics: Cashed Up With Catalysts Ahead
CytomX Therapeutics to Present at Upcoming June Investor Conferences
CytomX Therapeutics Appoints Mamata Gokhale, Ph.D., RAC, as Senior Vice President of Regulatory Affairs
CytomX Therapeutics, Inc. (CTMX) Q1 2026 Earnings Call Transcript
CytomX Therapeutics (CTMX) Reports Q1 Loss, Beats Revenue Estimates
CytomX Therapeutics Announces Q1 2026 Financial Results and Provides Business Update
CytomX Therapeutics to Report First Quarter 2026 Financial Results on May 7, 2026